We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300308:SZSEZhongji Innolight Co., Ltd. Class A Analysis

Data as of 2026-03-11 - not real-time

CN¥554.68

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Zhongji Innolight is trading just above its 20‑day SMA (≈550) while still under the 50‑day SMA, indicating a modest bullish bias that is reinforced by a bullish MACD histogram and a neutral RSI around 48. The stock’s trailing P/E of over 70 dwarfs the industry average of 37, suggesting it looks overvalued on current earnings, yet a forward P/E near 18 and a projected EPS jump from 7.66 to 31.06 point to strong earnings growth ahead. With an ROE exceeding 40% and profit margins above 25%, the fundamentals are robust, and a low dividend payout (0.16% yield) coupled with ample cash reserves makes the dividend sustainable. Market sentiment is highly optimistic (Fear‑Greed Index 76.7 – “Extreme Greed”) and analysts rate the stock a strong‑buy with a median target around 689, implying roughly 22% upside, but the 30‑day volatility of 65% and a beta under 1 signal notable price swings and modest systematic risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price is near a technical support level with high short‑term volatility
  • Neutral RSI and bullish MACD suggest limited immediate upside
  • Extreme market greed could reverse quickly

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E around 18 aligns with expected earnings acceleration
  • ROE above 40% and strong profit margins underpin profitability
  • Analyst consensus strong‑buy with ~22% upside target

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust cash position and low dividend payout support reinvestment
  • Long‑term demand growth in optical communication equipment
  • Valuation likely to normalize as earnings catch up to current price

Key Metrics & Analysis

Financial Health

Revenue Growth102.10%
Profit Margin28.24%
P/E Ratio72.4
ROE44.70%
Debt/Equity6.59
P/B Ratio23.4
Industry P/E37.0

Technical Analysis

TrendNeutral
RSI48.6
SupportCN¥506.00
ResistanceCN¥599.04
MA 20CN¥550.19
MA 50CN¥585.97
MA 200CN¥383.48
MACDBullish
VolumeStable
Fear & Greed Index76.7

Valuation

Target PriceCN¥680.11
Upside/Downside22.61%
GradeFair
TypeGrowth
Dividend Yield0.16%

Risk Assessment

Beta0.69
Volatility65.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.